Business Opportunities

Sun Pharma rises 2.3% on nod for generic drug

Sun Pharmaceutical Industries scrip rose Rs 32 or 2.3 per cent to close the day at Rs 1,429.20 on reports of US Food and Drug Administration’s (USFDA’s) nod for a generic drug. - Taro files lawsuit against Sun in US - Sun, Caraco to file 30 marketing applications for generics - Sun Pharma"s US arm facing more trouble - Sun Pharma settles patent dispute with Astra Zeneca - Sun Pharma uses own plants for US market after after Caraco trouble - Lawsuit filed against Sun Pharma"s US arm The company is believed to have received final approval to market Caffeine Citrate in injection and oral solution. The stock opened at Rs 1,397 and made an intra-day high of Rs 1,441.70. The stock is trading 11 per cent lower than its 52-week high of Rs 1,600 reached on 19 May, 2009.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

Categories
Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business
News of the day
Dishman-Takamul JV aims $ 50 million by 2012
Dishman Arabia, the 50:50 joint venture between Dishman Pharmaceuticals & Chemicals and Saudi Arabia based Takamul, is bullish on touching a turnover of $50 million within two years of commencement of production at its JV plant in Riyadh.
Popular Articles

Acquisition cost of Bollywood films falls 30-60%
Broadcasters are increasingly opting for non-exclusive rights of films this year.

Where are MBA jobs?
The slowdown in the economy has resulted in several jobs shrinking and the companies are going slow in recruiting. But there are jobs for the MBA graduates, particularly in sales, FMCG, telecom and consulting areas among others.

© Copyright 2009